Placental transfer and mammary excretion of a novel angiotensin receptor blocker fimasartan in rats

1Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Fimasartan (FMS) is a potent angiotensin receptor blocker for the treatment of mild to moderate hypertension. This study aimed to evaluate the transfer of FMS to fetus and breast milk in rats. Methods: In order to study the transfer to the fetus and nursing pup, pregnant and nursing maternal rats were administered with FMS by a constant intravenous infusion to reach target plasma concentrations of 200 ng/mL and 100 ng/mL. The concentrations of FMS in plasma, placenta, amniotic fluid, fetus, and milk were determined by a validated LC-MS/MS assay. Results: Upon constant intravenous infusion, the plasma FMS concentration reached the target steady state concentrations (Css=200 ng/mL and 100 ng/mL) in 24 h. The tissue-to-plasma partition coefficients (Kp) for placenta, amniotic fluid, and milk were obtained based on the observed FMS concentrations in the tissues and Css. The Kp values for all tissues were not different between high (Css=200 ng/mL) and low (Css=100 ng/mL) dose groups. While the mean Kp of the placenta was 44.6-59.0 %, the mean Kp was 1.3-1.7 % for the amniotic fluid and 14.9-17.0 % for fetus. The mean Kp of milk was 10.4-15.2 %. Conclusions: Placental transfer and milk excretion of FMS was relatively lower compared to other angiotensin receptor blockers.

Cite

CITATION STYLE

APA

Kim, T. H., Kim, M. G., Shin, S., Chi, Y. H., Paik, S. H., Lee, J. H., … Shin, B. S. (2016). Placental transfer and mammary excretion of a novel angiotensin receptor blocker fimasartan in rats. BMC Pharmacology and Toxicology, 17(1). https://doi.org/10.1186/s40360-016-0080-y

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free